Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Actelion, Roche to develop and market immunological treatment

Executive Summary

Roche and Swiss biotech Actelion (endothelium receptor modulators) have agreed to jointly develop and sell Actelion's Phase I oral, once-daily sphingosine-1-phosphate-1 (S1P1) receptor agonist for several autoimmune diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register